Navigation Links
Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients
Date:8/22/2007

Program will build on other successful GAMMAGARD LIQUID and GAMMAGARD S/D [Immune Globulin Intravenous (Human)] patient programs pioneered by Baxter

DEERFIELD, Ill., Aug. 22 /PRNewswire-FirstCall/ -- Baxter International Inc. (NYSE: BAX) today announced that it will launch GARDian, an innovative program that helps provide continued access for patients relying on GAMMAGARD LIQUID and GAMMAGARD S/D [Immune Globulin Intravenous (Human)] (IGIV). IGIV products like GAMMAGARD LIQUID and GAMMAGARD S/D are immunoglobulin (IgG) replacement therapies containing broad-spectrum immunoglobulins and are indicated for patients with primary immunodeficiency. Primary immunodeficiency is a group of genetic disorders in which the immune system fails to produce adequate amounts of antibodies, thereby predisposing individuals to increased risk of infection.

IGIV users and physicians can experience changes involving their providers or site of care that can sometimes impede access to their preferred IGIV therapy. Baxter's GARDian program, which is expected to start early next year, will provide patients and physicians with continued access to GAMMAGARD LIQUID and GAMMAGARD S/D even when such changes occur.

GARDian is viewed as a logical extension of other successful patient- centric programs pioneered by Baxter. The hallmark of each of these programs is continued access to GAMMAGARD LIQUID and GAMMAGARD S/D. They include:

-- GAMMAssist -- An innovative program that allows eligible users of

GAMMAGARD to continue to receive their immunoglobulin therapy in the

event of a lapse in insurance.

-- Low IgA/Brand Intolerance Program -- A program providing patient access

to GAMMAGARD S/D selected
'/>"/>

SOURCE Baxter International Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Merge launches diagnostic mammography workstation in Europe
2. Einstein Wireless launches cellular alert system
3. Logistics Health launches compliance management tool
4. UW-Madison launches new high-speed research network
5. UWM launches research foundation
6. Weather information companies launch data product
7. TeraMedica launches information manager
8. GE Healthcare launches hybrid electronic record
9. Cedara launches new version of DICOM toolkit
10. Merge launches Spanish version of imaging tool
11. Orbitec will use $25 million Air Force contract to make small launch vehicle
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 This webinar will focus on ... safety assessment in biosimilars. , Regulatory frameworks are evolving ... development, however the complex nature of biopharmaceuticals makes the ... efficacy extremely challenging. Based on the specific aspects of ...
(Date:1/15/2014)... January 15, 2014 The Microcompetition with Foreign ... disease. One of these latent viruses is the Epstein Barr ... (RA). Rheumatoid arthritis (RA) is a chronic inflammatory disease that ... study found that RA patients have high concentrations of EBV ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 AudioNotch is ... new therapy for the treatment of tinnitus. Patients listen ... frequency, and over a period of weeks to months, their ... Therapy in two forms: Notched Music and Notched White Noise. ...
(Date:1/14/2014)... CA (PRWEB) January 14, 2014 Histogen, ... the products of cells grown under simulated embryonic conditions, ... license agreement with Suneva Medical, Inc. for physician-dispensed aesthetic ... , This agreement is an amendment to ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3
... VANCOUVER, March 31 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. ... announced it has completed an Amended and Restated ... International Inc. (Baxter). As consideration for the Amended ... receive $25 million. , Angiotech and Baxter initially ...
... AG (VSE: ICLL) today announced that it will host ... and Drug Administration,s (FDA) approval of IXIARO(R), a new ... initial target for use of Intercell,s vaccine - the ... - will be adult travelers and military personnel who ...
... 31 DOR BioPharma, Inc. (OTC Bulletin Board: DORB) ... announced its financial results for 2008. DOR,s revenues for ... in 2007. The increase was due primarily to ... resulting achievement of certain research and development milestones with ...
Cached Biology Technology:Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc. 2Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc. 3Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc. 4Intercell to Host Conference Call and Webcast Today on FDA Approval of IXIARO(R) Japanese Encephalitis Vaccine 2Intercell to Host Conference Call and Webcast Today on FDA Approval of IXIARO(R) Japanese Encephalitis Vaccine 3DOR BioPharma Reports Year-End 2008 Financial Results and Reviews Recent Accomplishments 2DOR BioPharma Reports Year-End 2008 Financial Results and Reviews Recent Accomplishments 3DOR BioPharma Reports Year-End 2008 Financial Results and Reviews Recent Accomplishments 4DOR BioPharma Reports Year-End 2008 Financial Results and Reviews Recent Accomplishments 5
(Date:4/23/2014)... allergies and other chronic inflammatory disorders among people of ... their reduced exposure to the microbes that thrive in ... The article, published in the journal Clinical & ... centers who have less access to green spaces may ... caused by immune system dysfunction. , When our immune ...
(Date:4/23/2014)... their mid-thirties and forties, face a devastating prognosis: ... decades. "Mutant" protein clusters, long blamed for the ... primary focus of therapies in development by pharmaceutical ... Gerardo Lederkremer and Dr. Julia Leitman of Tel ... in collaboration with Prof. Ulrich Hartl of the ...
(Date:4/23/2014)... NY. (Apr. 23, 2014) People who have had ... to restore neurological function. However, a study conducted in ... of Cell Transplantation , but is currently freely ... http://www.ingentaconnect.com/content/cog/ct/pre-prints/content-ct1168Chen , has found that when one group of ... (PBSCs) injected directly into the brain and a similar ...
Breaking Biology News(10 mins):Rural microbes could boost city dwellers' health 2Rural microbes could boost city dwellers' health 3On the defensive 2On the defensive 3Autologous stem cell therapy improves motor function in chronic stroke victims 2
... Scientists at the Zucker Hillside Hospital campus of the ... markers that can increase a persons risk for schizophrenia. ... of the National Academy of Sciences, the research team ... be inherited in a recessive manner. A recessive trait ...
... have used ultraviolet light to sculpt three-dimensional microparticles ... and tissue engineering. For example, they could be ... molecules, such as DNA, or to release drugs ... control over the size, shape and texture of ...
... Journal of Lipid Research (Vol. 48, No. 12) ... Disease Increases Progression of Atherosclerosis, Breaking the Vicious Cycle ... Genetic Variants Affect Weight-Associated Cholesterol Metabolism ... alter how the body adjusts cholesterol metabolism in response ...
Cached Biology News:Feinstein researchers develop new genetic method and identify novel genes for schizophrenia 2MIT sculpts 3-D particles with light 2Story ideas from the Journal of Lipid Research 2Story ideas from the Journal of Lipid Research 3
Request Info...
"BioTracker 6X Bromophenol Blue Tracking Dye is composed of 60% St DI H2O, 30% Glycerol, 10% 10XTE, 0.25% BPB Dye and 0.85% SDS....
Agarose, low melting/gelling temperature, high MW separation (>1000 bp), 25 g. Suitable for enzymatic modifications. Nuclease-free.Gel point: 24-30 C, EEO (-mr): 300 gm/cm2. Category: Nucleotides &...
Request Info...
Biology Products: